|
Interessante Einschätzung von National Research. Yield10 Bioscience’s (NASDAQ:YTEN) Buy Rating Reiterated at National Securities Thursday, September 12th, 2019 https://rivertonroll.com/news/2019/09/12/yield10-bioscience-… The firm currently has a $5.00 price target company’s stock. - Additional Genes Now Under Consideration. The research license with Bayer (STU: BAY – NR – €66.48) has been amended to include an expanded scope for the C3004 trait. Under the original agreement signed in late 2017, BAY considered the C3003 and C3004 traits for evaluation in soybean, with the genes under consideration targeted to controlling carbon flow. With YTEN’s additional discoveries in the C3004 trait from 2018 trials in camelina, the research license was expanded to include a broader scope of genes. - A Validation Of Technology? We expect that since the December 2017 license was signed that BAY has studied the C3003 and C3004 traits within its soybean varieties in greenhouse settings, and moved to field trials in Spring 2019. We believe that BAY could easily terminate the agreement if it saw no commercial potential, and we believe the expanded scope represents a validation of YTEN technology. - No Better Commercial Partner. Following BAY’s acquisition of Monsanto, it controls roughly one third of global soybean sales, and its overall market share is significantly greater when considering seed distributed by peers which include BAY licensed traits. We believe of the major commercial crops that there is no better partner for YTEN than BAY and its soybean market. - Additional Agreements Needed, May Come With Funded R&D. We anticipate that YTEN is in active discussions with other commercial partners and believe future research agreements may come with a funded R&D component.,” National Securities’ analyst wrote. |
|
| aus der Diskussion: | YTEN - Yield10 Bioscience, Inc - Research License deal mit Monsanto |
| Autor (Datum des Eintrages): | iknowtheway (10.10.19 13:50:50) |
| Beitrag: | 46 von 65 (ID:61665048) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |